RET-Positive Thyroid Gland Carcinoma — Trials

RET-Positive Thyroid Gland Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 0
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: —
Top sponsor: —
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03131206	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer	terminated	Phase 1 / Phase 2	5	Dana-Farber Cancer InstituteOTHER	1	Sep 27, 2021	clinicaltrials

Data updated 22 days agoSource updated Sep 27, 2021source: clinicaltrials